EI
PBYI icon

EAM Investors’s Puma Biotechnology PBYI Stock Holding History

EAM Investors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-272,787
Closed -$1.15M – 336
2022
Q4 		$1.15M Buy
+272,787
New +$941K 0.24% 199
2018
Q1 		– Sell
-17,987
Closed -$1.78M – 343
2017
Q4 		$1.78M Sell
17,987
-5,209
-22% -$583K 0.32% 153
2017
Q3 		$2.78M Buy
+23,196
New +$2.16M 0.37% 82
2016
Q4 		– Sell
-56,263
Closed -$3.77M – 347
2016
Q3 		$3.77M Buy
+56,263
New +$2.84M 0.51% 33
2015
Q1 		– Sell
-10,379
Closed -$1.96M – 379
2014
Q4 		$1.96M Buy
10,379
+4,920
+90% +$1.09M 0.27% 170
2014
Q3 		$1.3M Buy
+5,459
New +$1.12M 0.26% 173

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

EAM Investors's PBYI Position: Q1 2023 in Review

EAM Investors sold out of Puma Biotechnology (PBYI) in Q1 2023, closing a stake of 272,787 shares — an estimated $1.15M sold.

EAM Investors first reported a position in PBYI in Q3 2014 and held it in 6 quarters. The position peaked at $3.77M in Q3 2016. 77 funds tracked by Wall St. Rank hold PBYI as of Q1 2023.

  • EAM Investors reported no remaining Puma Biotechnology position as of Q1 2023 after selling out during the quarter.
  • EAM Investors sold 272,787 Puma Biotechnology shares in Q1 2023, an estimated $1.15M.
  • EAM Investors first reported a position in Puma Biotechnology in Q3 2014 and held it in 6 quarters.
  • EAM Investors's Puma Biotechnology position peaked at $3.77M in Q3 2016.
  • 77 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.